A one-year study on the pharmacodynamic profile of interferon-β1a in MS

被引:12
作者
Bagnato, F
Pozzilli, C
Scagnolari, C
Bellomi, F
Pasqualetti, P
Gasperini, C
Millefiorini, E
Galgani, S
Spadaro, M
Antonelli, G
机构
[1] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dept Expt Med & Pathol, Virol Sect, I-00185 Rome, Italy
[3] San Camillo Hosp, Neurol Sect, Rome, Italy
[4] Univ Roma La Sapienza, Inst Neurol, Rome, Italy
关键词
D O I
10.1212/WNL.58.9.1409
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
引用
收藏
页码:1409 / 1411
页数:3
相关论文
共 10 条
[1]   NEOPTERIN AUGMENTATION OF TUMOR-NECROSIS-FACTOR PRODUCTION [J].
BARAK, M ;
GRUENER, N .
IMMUNOLOGY LETTERS, 1991, 30 (01) :101-106
[2]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[3]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[4]   THE ROLE OF NEOPTERIN AS A MONITOR OF CELLULAR IMMUNE ACTIVATION IN TRANSPLANTATION, INFLAMMATORY, INFECTIOUS, AND MALIGNANT DISEASES [J].
FUCHS, D ;
WEISS, G ;
REIBNEGGER, G ;
WACHTER, H .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1992, 29 (3-4) :307-341
[5]   Neopterin: a review [J].
Hamerlinck, FFV .
EXPERIMENTAL DERMATOLOGY, 1999, 8 (03) :167-176
[6]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[7]  
MESSNER RP, 1984, J LAB CLIN MED, V104, P141
[8]   Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers [J].
Rothuizen, LE ;
Buclin, T ;
Spertini, F ;
Trinchard, I ;
Munafo, A ;
Buchwalder, PA ;
Ythier, K ;
Biollaz, J .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 99 (01) :131-141
[9]   THE INTERFERONS - BIOLOGICAL EFFECTS, MECHANISMS OF ACTION, AND USE IN MULTIPLE-SCLEROSIS [J].
WEINSTOCKGUTTMAN, B ;
RANSOHOFF, RM ;
KINKEL, RP ;
RUDICK, RA .
ANNALS OF NEUROLOGY, 1995, 37 (01) :7-15
[10]   Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron® and AVONEX™ [J].
Williams, GJ ;
Witt, PL .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (11) :967-975